VANCOUVER, BC September 25 2019 (FSCwire) Experion Holdings Ltd. (TSXV: EXP) (OTCQB: EXPFF) (FRANKFURT: MB31), formerly Viridium Pacific Group the parent company of Experion Biotechnologies Inc., a Health Canada licensed cultivator and processor of Cannabis and EFX Laboratories Inc., a medical product’s production and and clinical research company based in Calgary, AB. is pleased to provide an update on its core business strategy and operational activities.
Mr. Jay Garnett, Chief Executive Officer, commented, “Over the past weeks, we have made great strides executing our focused strategy on key initiatives that will best position Experion to be a significant player in the cannabis space. We believe that as the cannabis industry matures, the market will reward focused companies that can monetize their assets. This paradigm shift is starting to show as investors are becoming focused on companies that are charting a path to profitability. We are placing a strong focus on the medical cannabis segment, where we see an un-matched market opportunity, both domestically and internationally.”
Highlights discussed in the update:
- Experion’s entry into the Hemp-CBD market
- Experion expands national footprint signs Quebec Letter of Intent
- Experion’s Product Update – Recreational and Health and Wellness
- Experion’s Medical Cannabis Focus Update
- Experion – CEO Podcast Interview with Equity Guru “Experion Holdings and the Art of Executive Accountability”
Experion’s Enters the Hemp-CBD market with Equity Investment into Top-Tier Hemp Producer, True North Cannabis Inc.
On Tuesday, September 17, Experion announced that the Company had entered a non-binding term sheet as well as making an equity investment into True North Cannabis Corp. The Equity Investment is important for Experion and aligns with the Company’s strategy to secure long-term quality supply agreements through strategic investments in the supply chain.
Chief Operating Officer, Mr. Jarrett Malnarick commented, “The investment into True North gives Experion direct access to True North’s premium hemp-based CBD Biomass. To start, we will have access to some 6,000 kilograms of high-potency hemp-based CBD Biomass for the 2019 harvest and at least 6,000 kilograms for each year going forward. Direct access to quality product is key as Experion positions to be a contender in the hemp-CBD sector.
The industrial Hemp market is forecasted to reach $13.03 billion (USD) by 2026. We have seen a surging demand for industrial Hemp in end-use applications and will be a significant factor to stimulate market growth both nationally and internationally. Experion sees Hemp derived CBD products as a way to leverage access in the US as several US companies have approached us for co-branding opportunities in both countries. Furthermore, in Europe and beyond, the hemp market opportunity is expanding as well; with early acceptance for Hemp-derived CBD products in various countries in the EU, Mexico and Asia. In Canada, Cannabis 2.0 Legalization is a significant near-term catalyst for Experions’ health and wellness products under the brand Kanabé Goods Co. (“Kanabé”). Experion is better -positioned to take advantage of Health Canada’s final regulations for Value-Added Products scheduled to come into effect on October 17, 2019 by securing a high-quality Hemp supply”.
The Company will look to pursue further farming agreements as outdoor cannabis production becomes mainstream allowing long term access to inexpensive biomass for value-added products.
Experion LOI with the Societe Quebecoise Du Cannabis (SQDC)
On Tuesday, September 10, Experion announced that the Company signed a letter of intent with the Societe Quebecoise du Cannabis (SQDC), Quebec’s sole legal retailer of recreational cannabis, to supply adult-use cannabis products to the SQDC for distribution and sale in Quebec.
Mr. Jay Garnett further commented, “The LOI with the SQDC is a pivotal moment for Experion as it gives us access to a market size of over 8.4 million the second largest population in Canada. From the public information available, Experion will be the fourth supplier of capsules next to Aurora, Canopy, and MedReleaf within the Quebec market.”
Experion Product Update
Last week, Experion shipped its second commercial retail Adult-Use strain to the provinces of British Columbia and Saskatchewan. Experion has a portfolio of high-quality strains for both the Adult-Use, health and wellness markets that include products which can provide unique experiences and medical benefits and are commercially viable in quality and consistency. Experion also continues to develop grow partnerships allowing us to increase our canopy size with our premium genetics. Experion now has over 4,000 clones actively growing with our partners with several more opportunities on the horizon with the ability to double capacity again in the near term.
Experion is also continuing to develop new processing capabilities at its Mission facility that include a variety of extraction methods and oil concentration as well as, new product development for the emerging Value-Added Products market. We will keep the market informed as they become available.
Experion’s Medical Cannabis Focus Update
Experion continues to foster its partnership agreements in Germany and Poland as part of the Company’s focus on international expansion through medical cannabis products as an entry way into the European markets.
Mr. Jay Garnett further commented, “We are excited about the long-term potential of the European and emerging cannabis markets. Europe is forecasted to have a market share of 28% in the year 2026. Germany is the largest market for cannabis and thereby fuels the market growth in this region.
COO, Jarrett Malnarick, and I traveled to Europe last week to meet with our existing and potential partners. Our meetings were extremely successful and further bolstered our belief of the opportunity in Europe. In Poland, we met with new partners to determine the best path forward to import product and support the emerging market developing in Poland. In Germany, we met our current partners to solidify current and future plans to supply the German medical market.
In addition, we leveraged our time in Frankfurt to present the Experion story to the investment community, we learned from presenting to over 35 distinct groups that there is a real appetite for the cannabis sector. The Experion investment opportunity was well received, and we feel that we have set a solid foundation on which to build on as we continue to execute our strategy”
CEO Podcast Interview with Equity Guru “Experion Holdings and the Art of Executive Accountability
Experion’s Chief Executive Officer, Jay Garnett recently sat down for a Podcast Interview with Equity Guru, titled, “Experion Holdings and the Art of Executive Accountability” here is the link to that Podcast Interview
About Experion Holdings Ltd.
Experion Holdings Ltd. is the parent company of Experion Biotechnologies Inc., a Health Canada licensed cultivator and processor of Cannabis, based in Mission, BC; and EFX Laboratories Inc., a medical products production and clinical research company based in Calgary, AB.
Experion Holdings Ltd. is invested in a portfolio of products to address a wide spectrum of consumer needs’ including
Medical, Adult-use, and Wellness and Therapeutic products.
Experion Holdings Ltd trades on the TSX Venture Exchange as a Tier 1 issuer under the symbol “EXP” on the OTCQB Venture under the symbol “EXPFF” and on the Frankfurt Stock Exchange under the symbol “MB31”
For further information, please visit the Company’s website www.experionwellness.com or join our Global Investor Forum on 8020 http://connects.company/ExperionEXP where you can read all press releases or contact Investor
Judy-Ann Pottinger, Investor Relations Manager
Phone: 604- 617-5290
This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.
Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company’s equity securities; recent market volatility; the Company’s ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management’s Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.